Opinion|Videos|September 18, 2024
Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM
The relapsed/refractory multiple myeloma experts conclude by highlighting current unmet needs in the field and sharing valuable clinical pearls to guide practice and improve patient outcomes.
Advertisement
Advertisement
Related to this article
The top 5 OncLive TV videos of the week.
The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Most patients treated with talquetamab at a single center would not have qualified for MonumenTAL-1, yet responses were similar regardless of trial eligibility.
The top 5 OncLive TV videos of the week cover insights in MDS, multiple myeloma, pancreatic cancer, colorectal cancer, and uveal melanoma.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Nogapendekin Alfa Inbakicept Plus BCG for High-Grade, Papillary-Only BCG-Unresponsive NMIBC
2
Real-World, First-Line IO-Based Combos Are Associated With Improved OS vs TKI Monotherapy in Advanced RCC
3
Tenumomeran/Raplemomeran Plus Pembrolizumab Misses PFS End Point in HPV16+ HNSCC
4
FDA Accepts BLA Resubmission for Tabelecleucel in EBV+ Post-Transplant Lymphoproliferative Disease
5